Balancing the interplay of histone deacetylases and non-coding genomes: a step closer to understand the landscape of cancer treatment

Histone deacetylase (HDAC) inhibitors have enormous therapeutic potential as effective epigenetic regulators, and now with the focus on the selective HDAC6 inhibitor in ongoing clinical trials, more advantages over other non-selective pan-HDAC inhibitors are foreseeable. As it is of paramount import...

Descripción completa

Detalles Bibliográficos
Autores principales: Pu, Jingjing, Liu, Ting, Sharma, Amit, Schmidt-Wolf, Ingo G. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10657130/
https://www.ncbi.nlm.nih.gov/pubmed/37978516
http://dx.doi.org/10.1186/s12920-023-01724-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10657130/
https://www.ncbi.nlm.nih.gov/pubmed/37978516
http://dx.doi.org/10.1186/s12920-023-01724-3

Ejemplares similares